Vincent DiGiacomo
Director, Therapeutic Innovation Jorna Therapeutics
Dr. Vincent DiGiacomo is a co-founder and Vice President of Translation at Jorna Therapeutics with expertise in human pathobiology and conducting large screening campaigns to identify therapeutic agents. Coming from a background in small molecule drug design, he has worked across several major disease areas and in the fields of structural biology and protein/mutation modeling. Throughout his career, Dr. DiGiacomo has acquired a deep knowledge of cell signaling, system-level disease processes, and RNA-based therapies, leveraging this experience to develop therapeutics utilizing biochemical, cell-based, and animal models of human disease.
Seminars
• Utilizing transcriptomic data to assess peripheral sequences and empirically monitor off-target edits
• Designing guide RNA for maximum durability and specificity to limit toxicity and immunogenicity
• Determining safety thresholds and acceptable levels of off-target editing
• Identifying differentiated target sequences using human genomics data and AI
• Exploring editing ceilings and limitations of various targets
• Elucidating treatable diseases and identifying patients with the suitable genotype who could benefit from treatment
